In the battle for market share and sales, Biogen Idec (BIIB-$46.75) has successfully conveyed the Tysabri message to providers and potential customers alike through popular social media websites ranging from YouTube to Facebook. Despite the increasing amount of PML cases that have been diagnosed since Tysabri was re-introduced to the U.S. market in July 2006, neurologists’ confidence in the drug remains strong – with 63 percent of providers agreeing to a survey statement: “Tysabri’s benefits outweigh the risk it poses to MS patients.”
Notwithstanding the drug’s known efficacy, would it not be interesting to find out (a) to what extent do busy physicians rely on the Internet for drug education and updates? And, (b) how much of this information originates from company-sponsored sources?
To read more about Biogen’s web-enabled social media strategies, click though to BNET Pharma….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
Notwithstanding the drug’s known efficacy, would it not be interesting to find out (a) to what extent do busy physicians rely on the Internet for drug education and updates? And, (b) how much of this information originates from company-sponsored sources?
To read more about Biogen’s web-enabled social media strategies, click though to BNET Pharma….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
No comments:
Post a Comment